Catalent Announces Two Senior Appointments To Biologics Business

Catalent Announces Two Senior Appointments To Expand Biologics Business

Somerset, NJ – February 26, 2014  — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced two senior appointments to further strengthen its global biologics business.

Andrew Sandford joins Catalent as Vice President Business Development, Biologics, and will focus on growth of the company’s existing biologics offerings, including the recently completed Biomanufacturing Center of Excellence in Madison, WI, and its high-performance production cell line offering based on the proprietary  GPEx® system, as well as Catalent’s new SMARTag™ ADC technology. In addition, he will focus on driving global business and licensing opportunities to deliver sustainable long-term growth.

Mr. Sandford previously served as the Vice President of Business Development for Selexis, Inc., a subsidiary of Selexis SA, where he established the U.S. subsidiary of the company and was responsible for global transactional and strategic value creation.

Prior to this, he worked with Dow Chemical's Ventures Business Unit; Dowpharma, and Cambrex Biopharma, which was latterly acquired by Lonza Biologics.

A microbiologist by education, Mr. Sandford holds a BS from the State University of New York at Plattsburgh.

In a newly created role, Catalent has also appointed Dr. Jennifer Mitcham as Director, Business Development for Antibody-Drug Conjugates (ADC), Biologics.

Dr. Mitcham will focus on driving the development pipeline and global customer base for the SMARTag ADC technology platform. She joins Catalent from Theraclone Sciences where she was Senior Director, Program Management, responsible for the development of the lead clinical antibody therapeutic program. Prior to Theraclone, Dr. Mitcham was with Corixa Corporation where she managed the oncology antibody development portfolio and was a Group Leader in Tumor Antigen Discovery.

Dr. Mitcham conducted her postdoctoral research at Immunex Corp, now Amgen, and holds both a BS in Biochemistry & Biophysics from Texas A&M University and a PhD in Molecular Genetics from University of Colorado Boulder.

“Andrew and Jennifer bring a wealth of experience to Catalent as we look to significantly grow our Biologics business,” commented Jonathan Arnold, Vice President & General Manager of Catalent Biologics. “Andrew has successfully launched biologics technology platforms in his previous roles and this will prove invaluable in support of our SMARTag technology. Jennifer has experience in drug development and has been a customer of Catalent’s proprietary GPEx technology for over ten years.”

About Catalent

Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.  With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in Fiscal 2013 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit .

More products. Better treatments. Reliably supplied.™